Target intelligence / Profile preview

Potassium voltage-gated channel subfamily D member 1 (KCND1)

Target
KCND1
Molecular classification
Ion channel, Voltage-gated potassium channel
01

Overview

Potassium voltage-gated channel subfamily D member 1 (KCND1) is a pore-forming alpha subunit of the A-type voltage-gated potassium channel family (Kv4.1). It is a multipass membrane protein essential for mediating the fast, transient outward potassium current (I_A) in excitable cells, notably within the brain and heart. KCND1 plays a key role in the repolarization phase of action potentials, thereby contributing to the regulation of neuronal firing patterns, circadian rhythms, cardiac conduction, hormone secretion (such as insulin), and smooth muscle contraction. Dysregulation or genetic variants of KCND1 are associated with diseases including epilepsy and Long QT syndrome, and research suggests a possible role in cancer cell proliferation. The channel's activity is modulated by regulatory subunits and biochemical factors, but it remains primarily a research target rather than a current therapeutic target in clinical practice[1][2][4][6].

Other names
Kv4.1Shal-type potassium channel KCND1Voltage-gated potassium channel subunit Kv4.1A-type voltage-gated potassium channel KCND1Potassium voltage-gated channel, Shal-related subfamily, member 1Potassium channel, voltage gated Shal related subfamily D, member 1Shal-type potassium channel
02

Mechanism of action

Drugs that inhibit A-type voltage-gated potassium channels reduce the A-type potassium current (I_A), affecting neuronal excitability, action potential repolarization, and possibly circadian patterns[4][1].

03

Biological functions

Transmembrane potassium transportRegulation of membrane action potential repolarizationRegulation of neurotransmitter releaseRegulation of heart rateRegulation of insulin secretionRegulation of neuronal excitabilitySmooth muscle contraction
04

Disease associations

Long QT syndromeEpilepsyPotential role in cancer cell proliferation (specifically mammary epithelial cells)
05

Safety considerations

Systemic inhibition of Kv4.1 channels may impact cardiac conduction, neuronal excitability, and hormone secretion, leading to potential arrhythmias, neurological side effects, or metabolic disturbances[1][4].
06

Interacting drugs

No widely used or approved drugs directly targeting KCND1/Kv4.1 are documented; research compounds and small-molecule blockers of A-type potassium channels may interact, but none are in standard clinical use[1][6].
07

Biomarkers

No established clinical biomarkers for KCND1 in patient selection or monitoring[1][6].

Beyond the preview

Go deeper on Potassium voltage-gated channel subfamily D member 1 (KCND1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium voltage-gated channel subfamily D member 1 (KCND1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call